Grifols to begin trial of inhaled alpha1-proteinase inhibitor for CF
This article was originally published in Scrip
Executive Summary
Spanish firm Grifols has announced plans to begin a safety trial of a next-generation inhaled formulation of alpha1-proteinase inhibitor later this year. The news follows the decision by the US FDA to grant orphan drug designation to the product for cystic fibrosis in April.